Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
Launched by BEIJING TIANTAN HOSPITAL · Feb 12, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how moyamoya disease affects thinking and memory. Researchers want to identify what might lead to cognitive decline in patients with this condition. They will use brain imaging to look for areas that may be damaged and study changes in the brain after a treatment called cerebral revascularization, which aims to improve blood flow to the brain. The goal is to see how these changes might relate to improvements in thinking skills.
To participate in this study, individuals must be between 18 and 60 years old and have been diagnosed with moyamoya disease through a specific brain imaging test. Participants will need to sign a consent form agreeing to take part. However, people with certain other health conditions or who cannot undergo brain imaging will not be eligible. Those who join the trial can expect to undergo brain imaging and cognitive assessments to help researchers understand the relationship between brain health and cognitive function in moyamoya disease. The study is currently recruiting participants, so there are opportunities to get involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
- • Please sign the informed consent form.
- • Participants must be between 18 and 60 years of age.
- Exclusion Criteria:
- • Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.
- • Individuals younger than 18 years or older than 60 years.
- • Those with contraindications for magnetic resonance imaging.
- • Patients who are unable to complete cognitive brain assessments
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported